Inhaled Isopropyl Alcohol Versus Placebo to Manage Nausea at Electronic Dance Music Festivals
NCT ID: NCT04307550
Last Updated: 2025-04-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
55 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-12
Study Completion Date
2024-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
BACKGROUND
Studies have shown that isopropyl alcohol inhalation is effective for the relief of nausea in the emergency department. A 2016 randomized controlled trial found that nasally inhaled isopropyl alcohol achieved better nausea relief compared to placebo during a 10-minute period. In 2018, another randomized controlled trial showed that nasally inhaled isopropyl alcohol with or without oral ondansetron provided greater relief for nausea than oral ondansetron alone.
QUESTION
In electronic dance music festival attendees, who present with nausea to the medical team, how does inhaled isopropyl alcohol compare with inhaled sterile saline (placebo) for self-reported nausea 10-minutes post-intervention?
METHODS
Canadian electronic dance music festival attendees who present with nausea to the medical team, will be recruited until sample size reaches at least 70. Inclusion criteria will be festival attendees aged 18+ with a complaint of nausea. Exclusion criteria will include known allergy to isopropyl alcohol, inability to inhale through the nares, inability to report level of nausea, or already have taken an anti-nauseant.
After obtaining consent, participants will be randomized into two study arms. Arm 1 will nasally inhale an isopropyl alcohol pad with 10 deep inhalations (intervention). Arm 2 will nasally inhale a sterile saline pad with 10 deep inhalations (placebo). The pad must be within 2cm from the nares to ensure delivery. According to a study in 2002, isopropyl alcohol pad inhalation, dosed at 3 inhalations every 5 minutes for 3 doses, was not significantly different than standard treatment for relief of nausea. 10 inhalations exceeds the 9-dose total reported in the paper, and a one-time bolus dose of 10 inhalations, for the population and festival context, is more feasible in terms of patient compliance and patient flow.
After randomization, participants will rate their nausea on a numeric response scale (0 to 10, where 0 is no nausea and 10 is "worst nausea imaginable"). 10-minutes post-inhalation (isopropyl alcohol or placebo), participants will be asked to rate their nausea again.
The primary outcome is self-reported nausea scores 10-minutes post-intervention. The secondary outcome is the presence or absence of any vomiting spells 10-minutes post-intervention, as well as the presence or absence of rescue-medication needed 10-minutes post-intervention.
Studies have shown that isopropyl alcohol inhalation is effective for the relief of nausea in the emergency department. A 2016 randomized controlled trial found that nasally inhaled isopropyl alcohol achieved better nausea relief compared to placebo during a 10-minute period. In 2018, another randomized controlled trial showed that nasally inhaled isopropyl alcohol with or without oral ondansetron provided greater relief for nausea than oral ondansetron alone.
QUESTION
In electronic dance music festival attendees, who present with nausea to the medical team, how does inhaled isopropyl alcohol compare with inhaled sterile saline (placebo) for self-reported nausea 10-minutes post-intervention?
METHODS
Canadian electronic dance music festival attendees who present with nausea to the medical team, will be recruited until sample size reaches at least 70. Inclusion criteria will be festival attendees aged 18+ with a complaint of nausea. Exclusion criteria will include known allergy to isopropyl alcohol, inability to inhale through the nares, inability to report level of nausea, or already have taken an anti-nauseant.
After obtaining consent, participants will be randomized into two study arms. Arm 1 will nasally inhale an isopropyl alcohol pad with 10 deep inhalations (intervention). Arm 2 will nasally inhale a sterile saline pad with 10 deep inhalations (placebo). The pad must be within 2cm from the nares to ensure delivery. According to a study in 2002, isopropyl alcohol pad inhalation, dosed at 3 inhalations every 5 minutes for 3 doses, was not significantly different than standard treatment for relief of nausea. 10 inhalations exceeds the 9-dose total reported in the paper, and a one-time bolus dose of 10 inhalations, for the population and festival context, is more feasible in terms of patient compliance and patient flow.
After randomization, participants will rate their nausea on a numeric response scale (0 to 10, where 0 is no nausea and 10 is "worst nausea imaginable"). 10-minutes post-inhalation (isopropyl alcohol or placebo), participants will be asked to rate their nausea again.
The primary outcome is self-reported nausea scores 10-minutes post-intervention. The secondary outcome is the presence or absence of any vomiting spells 10-minutes post-intervention, as well as the presence or absence of rescue-medication needed 10-minutes post-intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
NCT00936377
Acute Alcohol Withdrawal
COMPLETED
NA
Oxytocin Treatment of Alcohol Dependence
NCT02275611
Alcohol Withdrawal
Alcohol Dependence
COMPLETED
PHASE2
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
NCT01590277
Active Ethanol and Active Iomazenil
Active Ethanol and Placebo Iomazenil
Placebo Ethanol and Active Iomazenil
+4 more
COMPLETED
PHASE1
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
NCT00000264
Opioid-Related Disorders
Substance-Related Disorders
COMPLETED
NA
Using Neuroeconomics to Characterize State-Based Increases and Decreases in Alcohol Value
NCT04067765
Alcohol Use Disorder
Alcohol Drinking
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
POPULATION OF INTEREST
Participants will be recruited from electronic dance music (EDM) festivals in Canada. This population was chosen because festival participants often present to event medical staff with a complaint of nausea, in a setting where the availability of medical resources such as oral and intravenous anti-nauseants are more limited than an emergency department. Although the effectiveness of isopropyl alcohol pads as anti-nauseant therapy has been demonstrated in hospital emergency rooms, no prior studies, to the investigators' knowledge, have assessed outcomes in festival populations. This study will be conducted by adapting protocols from prior studies that examined the effects of inhaled isopropyl alcohol on patient-reported nausea and will add to the current state of knowledge by investigating a novel population.
EDM events are included in this study, because the investigators have long-standing experience working at these festivals as part of the main medical team, responsible for providing medical care to all festival participants. Odyssey Medical, the organization that oversees all medical staff at these EDM events, has granted the investigators permission to integrate the proposed research study into patient care at these festivals. This organization recruits multi-disciplinary volunteers (physicians, nurses, respiratory therapists, pharmacists, lifeguards, paramedics, and first aiders) to manage the medical needs of festival attendees.
PARTICIPANT SCREENING
Participants will verbally respond to screening questions, with responses recorded electronically by Research Personnel #1 (aka "the assessor") on a secure Google Form (printed copies will be available as back-up). Individuals who satisfy all inclusion/exclusion criteria will continue in the study, while those who do not meet criteria will receive standard medical care as needed (e.g. oral or intravenous anti-nauseant).
Consent to participate in the study will be obtained with a signature, after review of a written consent form. For the consent process, the investigators will have a witness from the medical team. For all individuals with a complaint of nausea, the assessor will outline the purpose of the study, clarify risks/benefits, and highlight that participation is voluntary and can be withdrawn, before seeking consent. Given that festival participants may be intoxicated with substances, Research Personnel #1 will determine whether the participant has the mental capacity to continue with the study. Research Personnel #1 will confirm the person's name, sex, and age. If the participant is unable to report their name, sex, and age accurately (using the patient's chart as a comparator or a friend/family member), then this implies that the participant is not oriented enough (e.g., potentially too intoxicated) to continue the study; this participant would not continue with the study. Also, if the participant cannot verbalize a pre-treatment nausea score (e.g., tries to communicate with fingers or body language, asks a friend to translate, etc.), then this implies that they may be too intoxicated to use their own cognitive capacity to determine a specific number and then verbalize it; this participant would not continue with the study.
If consent is granted, the following information about the participant will be collected throughout the study:
* Numerical identification number (will be assigned based on the order of recruitment, e.g. participant 001, participant 002)
* Age
* Sex
* Self-reported alcohol consumed
* Self-reported recreational drugs ingested
* Self-reported other suspected contributors of nausea (e.g. migraine, head injury, pregnancy, infection)
* Pre-treatment nausea level (0-11)
* Absence/presence of emesis prior to treatment
* 10-minute post-treatment nausea level (0-11)
* Absence/presence of emesis post-treatment
* Any side effects or additional symptoms post-treatment
No uniquely identifying information such as name, birth date, or Provincial Health Care number will be recorded at any point of the study to preserve anonymity. Age and sex will be recorded alongside screening criteria and will be linked with each individual's data for future subgroup analyses, but this broad information is not expected to interfere with anonymity.
PARTICIPANT RANDOMIZATION
Included participants will be assigned to one of two study arms through randomization, facilitated by an electronic random number generator operated by Research Personnel #2 (i.e. "the intervention provider"), who will not be present for the baseline screening assessment.
INTERVENTION DELIVERY
Research Personnel #2 will then deliver the intervention according to the assigned study arm. Participants in Arm 1 will nasally inhale an isopropyl alcohol pad with 10 inhalations (intervention). Participants in Arm 2 will nasally inhale a sterile saline pad of similar appearance with 10 inhalations (placebo). Research Personnel #2 will remove the packaging out of participants' sight, in order to ensure participants are blinded to the identity of the inhaled substance. The isopropyl alcohol pad, or sterile saline pad, will be held within 2cm of participants' nares to ensure delivery during inhalations, as a 2018 study demonstrated success using isopropyl alcohol aromatherapy as an anti-nauseant when inhaled from 1-2cm from the nares.
According to a 2002 study, isopropyl alcohol pad inhalation, dosed at 3 inhalations every 5 minutes for 3 doses, was not significantly different than standard anti-nauseant treatment for relief of nausea. 10 inhalations exceeds the 9-dose total reported in the paper, and a one time bolus dose of 10 inhalations, for this population and festival context, is more feasible in terms of patient compliance and patient flow in the main medical area. Two other studies' protocols involved inhaling isopropyl alcohol, as many times as participants desired, within a few minutes. With all protocols taken into consideration, the investigators have determined that 10 inhalations is an appropriate threshold for potential anti-nauseant effect.
OUTCOME ASSESSMENT
After Research Personnel #2 (aka "the intervention provider") has ensured that the intervention/placebo has been inhaled, they will leave the participant's bedside to prevent them from biasing any subsequent outcome assessment, given their knowledge of the study arm. The intervention provider will not disclose the identity of the inhaled substance to the participant nor to the assessor.
10 minutes post-inhalation, Research Personnel #1 (aka "the assessor"), will return and assess the participant's nausea using the same 11-point numerical scale prior to treatment. Participants will also be asked to report any new symptoms in order to aid the identification of possible adverse outcomes. Presence or absence of vomiting pre- and post-intervention will also be recorded.
After the data collection is complete, both the intervention and control arms will be offered further treatment by medical staff if their nausea has not subsided. These "rescue" (additional) therapies may include oral and/or intravenous anti-nauseants. The need for rescue medications will be recorded.
DATA ANALYSIS
For primary and secondary outcomes, data will be analyzed with a one-tailed repeated-measures t-test to see if there are any differences in self-reported nausea pre-intervention and 10-minutes post-intervention, between the means of the treatment arms.
Subgroup analyses will be performed, via repeated-measures t-test to see if there are any differences between the means of the treatment arms, by male sex, female sex, age (18-25, 25-34, 35+), alcohol ingested, any recreational substance ingested, alcohol plus other any recreational substance ingested, and self-reported other suspected contributors of nausea.
SAMPLE SIZE
Sample size for each group was calculated with the assumption that the outcome data fits a ratio scale (nausea is rated on a continuum, ranging from 0 to 10).
A sample size, for adequate study power, was performed with the following parameters:
* Study group design: two independent study groups
* Primary endpoint: continuous (means)
* Anticipated mean for isopropyl alcohol swab group: 3 +/- 3
* Anticipated mean for placebo group: 5
* Alpha: 0.05
* Power: 0.8
Previous work in 2016 found the median nausea score for the isopropyl alcohol pad group was 3 and for the placebo group, 6, in the emergency department. The investigators lowered the placebo group by 1 point, to 5, to be conservative in calculations. A 2018 study found that the standard deviation was up to 30, on scale of 0 to 100, for all treatment groups (when comparing inhaled isopropyl alcohol + oral ondansetron, inhaled isopropyl alcohol + oral placebo, and inhaled placebo + oral ondansetron); therefore, the investigators assume a standard deviation of up to 3, in their scale from 0 to 10.
The investigators calculated a minimum sample size of 46 to power the study. Given that the sample size is large enough, the central limit theorem supports the normality assumption; therefore, a parametric test was selected (repeated-measures t-test) for statistical analyses.
Participants will be recruited from electronic dance music (EDM) festivals in Canada. This population was chosen because festival participants often present to event medical staff with a complaint of nausea, in a setting where the availability of medical resources such as oral and intravenous anti-nauseants are more limited than an emergency department. Although the effectiveness of isopropyl alcohol pads as anti-nauseant therapy has been demonstrated in hospital emergency rooms, no prior studies, to the investigators' knowledge, have assessed outcomes in festival populations. This study will be conducted by adapting protocols from prior studies that examined the effects of inhaled isopropyl alcohol on patient-reported nausea and will add to the current state of knowledge by investigating a novel population.
EDM events are included in this study, because the investigators have long-standing experience working at these festivals as part of the main medical team, responsible for providing medical care to all festival participants. Odyssey Medical, the organization that oversees all medical staff at these EDM events, has granted the investigators permission to integrate the proposed research study into patient care at these festivals. This organization recruits multi-disciplinary volunteers (physicians, nurses, respiratory therapists, pharmacists, lifeguards, paramedics, and first aiders) to manage the medical needs of festival attendees.
PARTICIPANT SCREENING
Participants will verbally respond to screening questions, with responses recorded electronically by Research Personnel #1 (aka "the assessor") on a secure Google Form (printed copies will be available as back-up). Individuals who satisfy all inclusion/exclusion criteria will continue in the study, while those who do not meet criteria will receive standard medical care as needed (e.g. oral or intravenous anti-nauseant).
Consent to participate in the study will be obtained with a signature, after review of a written consent form. For the consent process, the investigators will have a witness from the medical team. For all individuals with a complaint of nausea, the assessor will outline the purpose of the study, clarify risks/benefits, and highlight that participation is voluntary and can be withdrawn, before seeking consent. Given that festival participants may be intoxicated with substances, Research Personnel #1 will determine whether the participant has the mental capacity to continue with the study. Research Personnel #1 will confirm the person's name, sex, and age. If the participant is unable to report their name, sex, and age accurately (using the patient's chart as a comparator or a friend/family member), then this implies that the participant is not oriented enough (e.g., potentially too intoxicated) to continue the study; this participant would not continue with the study. Also, if the participant cannot verbalize a pre-treatment nausea score (e.g., tries to communicate with fingers or body language, asks a friend to translate, etc.), then this implies that they may be too intoxicated to use their own cognitive capacity to determine a specific number and then verbalize it; this participant would not continue with the study.
If consent is granted, the following information about the participant will be collected throughout the study:
* Numerical identification number (will be assigned based on the order of recruitment, e.g. participant 001, participant 002)
* Age
* Sex
* Self-reported alcohol consumed
* Self-reported recreational drugs ingested
* Self-reported other suspected contributors of nausea (e.g. migraine, head injury, pregnancy, infection)
* Pre-treatment nausea level (0-11)
* Absence/presence of emesis prior to treatment
* 10-minute post-treatment nausea level (0-11)
* Absence/presence of emesis post-treatment
* Any side effects or additional symptoms post-treatment
No uniquely identifying information such as name, birth date, or Provincial Health Care number will be recorded at any point of the study to preserve anonymity. Age and sex will be recorded alongside screening criteria and will be linked with each individual's data for future subgroup analyses, but this broad information is not expected to interfere with anonymity.
PARTICIPANT RANDOMIZATION
Included participants will be assigned to one of two study arms through randomization, facilitated by an electronic random number generator operated by Research Personnel #2 (i.e. "the intervention provider"), who will not be present for the baseline screening assessment.
INTERVENTION DELIVERY
Research Personnel #2 will then deliver the intervention according to the assigned study arm. Participants in Arm 1 will nasally inhale an isopropyl alcohol pad with 10 inhalations (intervention). Participants in Arm 2 will nasally inhale a sterile saline pad of similar appearance with 10 inhalations (placebo). Research Personnel #2 will remove the packaging out of participants' sight, in order to ensure participants are blinded to the identity of the inhaled substance. The isopropyl alcohol pad, or sterile saline pad, will be held within 2cm of participants' nares to ensure delivery during inhalations, as a 2018 study demonstrated success using isopropyl alcohol aromatherapy as an anti-nauseant when inhaled from 1-2cm from the nares.
According to a 2002 study, isopropyl alcohol pad inhalation, dosed at 3 inhalations every 5 minutes for 3 doses, was not significantly different than standard anti-nauseant treatment for relief of nausea. 10 inhalations exceeds the 9-dose total reported in the paper, and a one time bolus dose of 10 inhalations, for this population and festival context, is more feasible in terms of patient compliance and patient flow in the main medical area. Two other studies' protocols involved inhaling isopropyl alcohol, as many times as participants desired, within a few minutes. With all protocols taken into consideration, the investigators have determined that 10 inhalations is an appropriate threshold for potential anti-nauseant effect.
OUTCOME ASSESSMENT
After Research Personnel #2 (aka "the intervention provider") has ensured that the intervention/placebo has been inhaled, they will leave the participant's bedside to prevent them from biasing any subsequent outcome assessment, given their knowledge of the study arm. The intervention provider will not disclose the identity of the inhaled substance to the participant nor to the assessor.
10 minutes post-inhalation, Research Personnel #1 (aka "the assessor"), will return and assess the participant's nausea using the same 11-point numerical scale prior to treatment. Participants will also be asked to report any new symptoms in order to aid the identification of possible adverse outcomes. Presence or absence of vomiting pre- and post-intervention will also be recorded.
After the data collection is complete, both the intervention and control arms will be offered further treatment by medical staff if their nausea has not subsided. These "rescue" (additional) therapies may include oral and/or intravenous anti-nauseants. The need for rescue medications will be recorded.
DATA ANALYSIS
For primary and secondary outcomes, data will be analyzed with a one-tailed repeated-measures t-test to see if there are any differences in self-reported nausea pre-intervention and 10-minutes post-intervention, between the means of the treatment arms.
Subgroup analyses will be performed, via repeated-measures t-test to see if there are any differences between the means of the treatment arms, by male sex, female sex, age (18-25, 25-34, 35+), alcohol ingested, any recreational substance ingested, alcohol plus other any recreational substance ingested, and self-reported other suspected contributors of nausea.
SAMPLE SIZE
Sample size for each group was calculated with the assumption that the outcome data fits a ratio scale (nausea is rated on a continuum, ranging from 0 to 10).
A sample size, for adequate study power, was performed with the following parameters:
* Study group design: two independent study groups
* Primary endpoint: continuous (means)
* Anticipated mean for isopropyl alcohol swab group: 3 +/- 3
* Anticipated mean for placebo group: 5
* Alpha: 0.05
* Power: 0.8
Previous work in 2016 found the median nausea score for the isopropyl alcohol pad group was 3 and for the placebo group, 6, in the emergency department. The investigators lowered the placebo group by 1 point, to 5, to be conservative in calculations. A 2018 study found that the standard deviation was up to 30, on scale of 0 to 100, for all treatment groups (when comparing inhaled isopropyl alcohol + oral ondansetron, inhaled isopropyl alcohol + oral placebo, and inhaled placebo + oral ondansetron); therefore, the investigators assume a standard deviation of up to 3, in their scale from 0 to 10.
The investigators calculated a minimum sample size of 46 to power the study. Given that the sample size is large enough, the central limit theorem supports the normality assumption; therefore, a parametric test was selected (repeated-measures t-test) for statistical analyses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Nausea
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Participants in Arm 1 will nasally inhale an isopropyl alcohol pad with 10 inhalations (intervention). Participants in Arm 2 will nasally inhale a sterile saline pad of similar appearance with 10 inhalations (placebo).
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Outcome Assessors
An intervention/care provider will remove the packaging so that participants will be unable to identify the inhaled substance. We acknowledge that the smell of isopropyl alcohol may be familiar and thus identifiable for some treatment arm participants. However, participants will not be informed of the identity of the treatment and placebo during the consent process, instead only being told that we are comparing two inhaled substances to assess their relative effectiveness. Thus, recognizing they are inhaling isopropyl alcohol should not bias participants' responses, given they will not know whether isopropyl alcohol is a treatment or control.
The outcomes assessor will be blinded, because the randomization and intervention delivery are both completed by the intervention/care provider, who will not be involved in screening/baseline assessment nor outcome assessments.
The outcomes assessor will be blinded, because the randomization and intervention delivery are both completed by the intervention/care provider, who will not be involved in screening/baseline assessment nor outcome assessments.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Isopropyl Alcohol
10 inhalations of an isopropyl alcohol pad held within 2cm from the nares
Group Type
EXPERIMENTAL
Isopropyl alcohol
Intervention Type
DRUG
10 inhalations of an isopropyl alcohol pad
Sterile Saline
10 inhalations of a sterile saline pad held within 2cm from the nares
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
10 inhalations of a sterile saline pad
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isopropyl alcohol
10 inhalations of an isopropyl alcohol pad
Intervention Type
DRUG
Placebo
10 inhalations of a sterile saline pad
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Isopropyl alcohol pad
Sterile saline pad
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Festival attendees aged 18+
* A complaint of nausea of at least 1 on a scale of 0 to 10 (11-point scale, where 0 represents "no nausea" and 10 represents "worst nausea imaginable").
* A complaint of nausea of at least 1 on a scale of 0 to 10 (11-point scale, where 0 represents "no nausea" and 10 represents "worst nausea imaginable").
Exclusion Criteria
* Known allergy to isopropyl alcohol (standard practice involves medical team members asking patients what allergies they have; we will not directly ask about isopropyl alcohol in order to keep participants blinded to interventions)
* Inability to inhale through the nares (e.g. distorted nasal anatomy, active nosebleed, obstructed nasal passages, rhinitis, anosmia)
* Inability to verbally report level of nausea
* Prior administration of an oral or intravenous anti-nauseant (e.g. metoclopramide, ondansetron, dimenhydrinate) by festival medical staff since arrival at the festival (would confound treatment effect)
* Inability to inhale through the nares (e.g. distorted nasal anatomy, active nosebleed, obstructed nasal passages, rhinitis, anosmia)
* Inability to verbally report level of nausea
* Prior administration of an oral or intravenous anti-nauseant (e.g. metoclopramide, ondansetron, dimenhydrinate) by festival medical staff since arrival at the festival (would confound treatment effect)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anthony Seto
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anthony Seto
Course Chair, "Intro to Clinical Practice"
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony V Seto, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Badlands Music Festival
Calgary, Alberta, Canada
Site Status
Chasing Summer Music Festival
Calgary, Alberta, Canada
Site Status
Family Reunion Music Festival
Calgary, Alberta, Canada
Site Status
Bomfest Music Festival
Edmonton, Alberta, Canada
Site Status
Hard West Music Festival
Wimborne, Alberta, Canada
Site Status
Electronic dance music festivals in Calgary
Calgary, , Canada
Site Status
Electronic dance music festivals in Edmonton
Edmonton, , Canada
Site Status
Electronic dance music festivals in Toronto
Toronto, , Canada
Site Status
Electronic dance music festivals in Vancouver
Vancouver, , Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
April MD, Oliver JJ, Davis WT, Ong D, Simon EM, Ng PC, Hunter CJ. Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial. Ann Emerg Med. 2018 Aug;72(2):184-193. doi: 10.1016/j.annemergmed.2018.01.016. Epub 2018 Feb 17.
Reference Type
BACKGROUND
Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl Alcohol Nasal Inhalation for Nausea in the Emergency Department: A Randomized Controlled Trial. Ann Emerg Med. 2016 Jul;68(1):1-9.e1. doi: 10.1016/j.annemergmed.2015.09.031. Epub 2015 Dec 8.
Reference Type
BACKGROUND
Merritt BA, Okyere CP, Jasinski DM. Isopropyl alcohol inhalation: alternative treatment of postoperative nausea and vomiting. Nurs Res. 2002 Mar-Apr;51(2):125-8. doi: 10.1097/00006199-200203000-00009.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB20-0288
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Mifepristone for the Prevention of Relapses of Alcohol Drinking
NCT02243709
COMPLETED
PHASE1/PHASE2
Effect of Endotoxin on Alcohol Consumption
NCT04527185
COMPLETED
PHASE2
Oxytocin Treatment of Alcohol Withdrawal
NCT01212185
COMPLETED
PHASE1
Interactive Effects of IV Ethanol and IV Nicotine
NCT01814410
COMPLETED
EARLY_PHASE1
Bristol Imperial MDMA in Alcoholism Study
NCT04158778
UNKNOWN
PHASE1
Ketone Ester Intervention in Alcohol Use Disorder
NCT04616781
RECRUITING
PHASE2/PHASE3
Using Imaging to Assess Effects of THC on Brain Activity
NCT03655717
COMPLETED
NA
CBD for the Treatment of Alcohol Use Disorder
NCT04873453
COMPLETED
PHASE2
Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers
NCT04596267
TERMINATED
PHASE1
MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
NCT03033823
COMPLETED
PHASE3
A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
NCT01531920
COMPLETED
PHASE1
Efficacy of Inhalation of Essential Oil on the Reduction of Inhalants Craving
NCT03296943
COMPLETED
PHASE3
Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
NCT03878316
COMPLETED
PHASE2
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
NCT06446479
RECRUITING
PHASE2
Effects of Combined Alcohol and Nitrous Oxide Intake - 15
NCT00000263
COMPLETED
NA
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
NCT02364947
COMPLETED
PHASE3
Psilocybin-assisted Therapy for Alcohol Use Disorder
NCT06444243
NOT_YET_RECRUITING
PHASE2
Computer-Assisted Self-Administration of Ethanol
NCT00713492
COMPLETED
PHASE1
Ketamine for the Treatment for Alcohol Use Disorder in the ED
NCT05661669
WITHDRAWN
PHASE2
Alcohol and Neural Cardiovascular Control in Binge Drinkers
NCT03567434
COMPLETED
NA
Oxytocin and Alcohol Withdrawal and Dependence
NCT02903251
COMPLETED
PHASE3
Neural Mechanisms Underlying Alcohol Induced Disinhibition
NCT01097213
COMPLETED
MAP4343 Treatment for Alcohol Use Disorder
NCT04157114
WITHDRAWN
PHASE2
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
NCT03430180
UNKNOWN
PHASE2